〔投行观点〕Hapoalim Securities给予Vanda Pharmaceuticals 买入的初始评级,目标价为23美元

〔投行观点〕Hapoalim Securities给予Vanda Pharmaceuticals 买入的初始评级,目标价为23美元

Posted by Fortune on 周三, 03/10/2010 - 22:57 in

((路透中文新闻部: 86-10-66271050; 传真 86-10-66019118; jianhua.tian@thomsonreuters.com; Reuters Messaging: jianhua.tian.thomsonreuters.com@reuters.net))

财富搜索